DIA 2021 Global Annual Meeting

Session Chair(s)

Responding and adapting to the changes invoked by the COVID-19 pandemic on clinical research foster new opportunities in many aspects of clinical research. At the heart of these opportunities are the need for statistical and analytical innovation. This session will highlight several areas where statistical and analytical innovation have informed our response to the COVID-19 pandemic and what this means for the future of clinical research. There will be a talk on the use of artificial intelligence for the rapid identification and determination of potential therapeutics that have the best chance of treating against those infected with the SAR-COV-2 virus. Another talk will discuss how the COVID-19 pandemic has magnified the vulnerability and unsustainability of the current clinical development which emphasizes the need to move towards more pragmatic, patient-centric, and adaptive trial designs that make extensive use of computer technology. The final talk will discuss how analytics and data visualization foster an ability to make timely decisions that impact the healthcare sector and clinical development.

Learning Objective : Describe the immediate, and potential long-term, impact of the COVID-19 pandemic on the clinical-research enterprise, both in terms of trials in this disease as well as non-COVID-19 trials.

Speaker(s)